NEW YORK, NY / September 22, 2022 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces that its project been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
A presentation named “Anticancer Gene Therapy Platform Addressing A Novel Target to Treat Patients” will showcase CLS’ data for the use of CLS-014 drug candidate as a platform technology to treat various cancers. CLS has identified a new therapeutic target for the successful anticancer therapy for multiple cancers: tumor- and neutrophils- derived cell-free DNA. Today, CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies. The Company uses smart chimeric AAV technology for the delivery of the DNase I transgene to the liver, after which, hepatocytes start to produce a recombinant human DNase enzyme that destroys this cell-free DNA within tumor tissue.
The data that will be presented by Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics.
NEW YORK, NY / April 06, 2021 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces presentation at the upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.
NEW YORK, NY / ACCESSWIRE / September 18, 2019 / CLS Therapeutics, a privately held oncology-focused gene therapy company developing a platform technology based on the identification of a novel therapeutic target that can be utilized for many cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLS-014 for the treatment of pancreatic cancer.h.
Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. (“CLS”) to Xenetic related to Xenetic’s previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) (“Volition”), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.